Preclinical Drug Testing in China: Events

• GLP Safety Studies in China: Analysis of Recent Experiences
  2/11/2010 
  On-Demand WebinarThis webinar originally took place on February 11, 2010Webinar detailsPanelists included senior executives from biopharmas that have recently conducted GLP safety studies at Chinese CROs. Panelists discussed their experiences, with a focus on why these companies decided to place their IND-enabling studies in China, and their conclusions about the advantages and disadvantages of that decision. Questions from the audience were included.Panelists: Ernie Bush (Managing Director, CPMS)Roger Anderson (COO, Qwell)Matthew Needham (Research Associate, Tosk)John Zhang (VP Preclinical R&D, EnzymeRx) Register now to listen to the archived version  

  
  

• How to Leverage China GLP Preclinical Study Services
  7/15/2009 
  Podcast (originally aired July 2009)  By: Ernest D Bush, PhD, Managing Director, CPMSThis podcast covers the current state of China's GLP Preclinical Study Services sector and what's required to realize the 35% to 50% potential cost savings and expedite NHP studies.Strategies being used by small, medium and large pharmas in ChinaFDA's acceptance of preclinical data from Chinese labsAdvantages of conducting NHP studies in ChinaThe importance of due diligence and project monitoringOptions for small and medium companies to manage a China Program Click here to listen to the archived version of this podcast.           

  
  

• Strategies for Leveraging Preclinical Capabilities in China
  6/24/2008 
  On-Demand Webinar (originally held 24 June 2008) This webinar focused on the variety of ways small and mid-sized pharmas are increasingly leveraging China labs to lower the cost and duration of their preclinical development programs. Based on our experience rigorously evaluating preclinical CROs in China, we have made the following observations:Preclinical capabilities in China can now be leveraged by biopharmas for substantial benefit including cost, speed and access to the Chinese marketChina’s CRO sector has greatly matured, and now many CROs offer robust global standard preclinical capabilities The challenge for small and mid-size biopharmas is to determine which partners to work with in China and for which studies.  Click here to listen to the archived version of this webinar.       

  
  

• The Impact of the July 2008 Covance-WuXi Joint Venture
  7/2/2008 
  On-Demand Webinar (originally held 2 July 2008) This online session focused on the Covnace-WuXi joint venture announced the previous week. Inquiries. The deal was a significant watershed event in the Chinese preclinical market with the potential to influence the decision-making processes of companies conisidering undertaking development work in China.The following points were covered:Why Covance and WuXi created the joint ventureIts potential to change pricing, services, and speed of growth in the pharma services sector in ChinaImplications on the competitive dynamics between providers (i.e. Bridge, WuXi, CRL-China, Medicilon-MPI, government labs, etc) Click here to listen to the archived version of this webinar.